BRAF and melanoma: In the real‐world study of patients with BRAF‐mutant advanced melanoma initiating 1L treatment, Luke et al (2019) reported that only 49.8% received 1L treatment, 43.5% received both 1L and 2L, and only 6.7% received 3L.29